KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) EBT Margin (2020 - 2026)

AbCellera Biologics filings provide 7 years of EBT Margin readings, the most recent being 595.75% for Q1 2026.

  • Quarterly EBT Margin rose 65534.0% to 595.75% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 219.86% through Mar 2026, up 69137.0% year-over-year, with the annual reading at 236.39% for FY2025, 45863.0% up from the prior year.
  • EBT Margin hit 595.75% in Q1 2026 for AbCellera Biologics, down from 43.47% in the prior quarter.
  • Across five years, EBT Margin topped out at 72.91% in Q1 2022 and bottomed at 1251.1% in Q1 2025.
  • Average EBT Margin over 5 years is 458.1%, with a median of 429.45% recorded in 2024.
  • Peak annual rise in EBT Margin hit 88383bps in 2025, while the deepest fall reached -82165bps in 2025.
  • AbCellera Biologics' EBT Margin stood at 145.8% in 2022, then crashed by -263bps to 529.49% in 2023, then tumbled by -75bps to 927.31% in 2024, then surged by 95bps to 43.47% in 2025, then crashed by -1270bps to 595.75% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's EBT Margin are 595.75% (Q1 2026), 43.47% (Q4 2025), and 767.93% (Q3 2025).